KAHR Medical Overview
KAHR is developing immuno-oncology drug candidates for the treatment of multiple types of cancer. Its lead product, DSP107, is a CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses, and activates an effective local response of both innate and adaptive immunity. KAHRs technology platform is based on multifunctional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells to selectively target and bind to the tumor. MIRPs bridge cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response while recruiting the adaptive immune system to bind and selectively kill the cancer cells. In August 2020, KAHR Medical received FDA clearance to begin clinical trials on its immunotherapy drug to battle cancer.
Cumulative Funding Raised Over Time ($)
$3.0MDec 2011
$15.0MDec 2015
$33.0MFeb 2020
$33.5MJan 2009
$80.0MJun 2021
$97.5MJun 2023
$97.5MJun 2024
$97.5MMar 2024
$97.5MMay 2025
$110.0MNov 2022
$117.5MSep 2013
$117.5MSep 2025
Latest News
growth-positive
/PRNewswire/ -- KAHR, a clinical-stage biotech company developing DSP107, a first-in-class bi-specific 4-1BB T-cell engager that activates innate and adaptive...
KAHR, a clinical-stage biotech company, announced positive results from the Phase 2 dose expansion cohort of DSP107 in combination with atezolizumab for treating 3rd line microsatellite stable metastatic colorectal cancer (MSS-CRC). The combination therapy has shown anti-tumor activity and extended survival, including in patients with liver metastases. These results will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. DSP107 is a bi-specific 4-1BB T-cell engager that activates both innate and adaptive immunity, targeting CD47 overexpression on cancer cells. This approach is particularly relevant for MSS-CRC, a challenging subtype of colorectal cancer. KAHRs development of DSP107 aims to address the unmet medical need in treating MSS-CRC.
Product StageFDA approved/pending approval
growth-positive
KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors
KAHR, a clinical-stage biotech company, announced positive results from a Phase I study of its novel immunotherapy, DSP107, in combination with atezolizumab. The study, which focused on patients with advanced solid tumors, demonstrated significant tumor shrinkage and durable responses, particularly in patients with microsatellite stable colorectal cancer (MSS-CRC). The highest dose of DSP107 was selected for Phase II expansion cohorts, showing a disease control rate of 57%. The treatment was well tolerated with no dose-limiting toxicities. These promising results will be presented at the ASCO 2023 Annual Meeting. KAHRs DSP107 targets CD47 and 4-1BB, activating both innate and adaptive immunity to treat solid tumors and blood cancers.
growth-positive
MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma
KAHR Medical has received an investment from the Myeloma Investment Fund (MIF) to explore the potential of its leading immunotherapy drug candidate, DSP107, for the treatment of multiple myeloma. The investment reinforces KAHRs commitment to developing innovative treatment approaches for myeloma patients. With this investment, KAHR Medical has raised a total of $59 million since June 2021. DSP107 is a dual-targeting fusion protein that activates innate and adaptive immunity to bolster anti-tumor immunity. It has demonstrated a good safety profile and high disease control rates in a phase 1 trial. MIF is a venture philanthropy fund that invests in promising companies and technologies in oncology to drive the development of new therapies for multiple myeloma.
Investment
growth-positive
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
KAHR and Cancer Focus Fund have announced the dosing of the first patient in a Phase 1b clinical trial of DSP107, a CD47x41BB targeting fusion protein, in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The trial is being funded by an investment from Cancer Focus Fund. KAHRs CEO, Yaron Pereg, expressed gratitude for the support and highlighted the potential of DSP107 to achieve significant anti-tumor effects across cancer types. The trial is being conducted at MD Anderson and led by Naval Daver. DSP107 is also being tested in a Phase 1/2 clinical trial for solid tumor cancers. KAHR develops novel dual-targeting fusion protein therapeutics that activate both the innate and adaptive immune systems.
Investment
growth-positive
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Cancer immunotherapy company KAHR has announced the first closing of an investment round, raising $46.5 million. The financing, led by aMoon, will be used to advance the clinical development of the companys lead product candidate, DSP107, a CD47x41BB targeting fusion protein for the treatment of solid and blood cancers. The funding will also support the development of KAHRs preclinical pipeline. The successful financing round includes participation from new and existing investors. KAHRs unique approach to cancer immunotherapy aims to unmask cancer cells for immune recognition and trigger a targeted activation of anticancer immunity. The companys lead product candidate, DSP107, is currently being tested in Phase 1/2 studies. KAHRs technology platform utilizes multi-functional immuno-recruitment proteins to selectively target and bind to tumors.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $117.5M |
| Last funding | Undisclosed |
| Stage | F |
| Rounds | 12 |
| Investors | 17 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | kahrbio.com/ |
Locations
Dam HaMacbim St 28, Modi'in-Maccabim-Re'ut, Israel
Photos & Videos
1 item(s)
KAHR Medical Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticalsCore Technology
BiologicalsCellsTags (9)
cancerbiological-therapydrug-deliverydrug-discoverypharmaceuticalsautoimmune-diseaseschronic-patientsbiopharmaceuticalpharma-companiesGeographic Markets
United StatesEuropeKAHR Medical Financials
$117.5M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
F
Funding stage
12
Total rounds
17
Investors
Cumulative Funding Raised Over Time ($)
$3.0MDec 2011
$15.0MDec 2015
$33.0MFeb 2020
$33.5MJan 2009
$80.0MJun 2021
$97.5MJun 2023
$97.5MJun 2024
$97.5MMar 2024
$97.5MMay 2025
$110.0MNov 2022
$117.5MSep 2013
$117.5MSep 2025
Private Equity Funding
Undisclosed Round
Sep 2025
Undisclosed
Peregrine Ventures
Undisclosed Round
May 2025
Undisclosed
Peregrine Ventures
Undisclosed Round
Jun 2024
Undisclosed
aMoon Fund
Undisclosed Round
Mar 2024
Undisclosed
Peregrine Ventures
F Round
Jun 2023
$17.5M
Peregrine Ventures
Undisclosed Round
Nov 2022
$12.5M
Myeloma Investment Fund
Undisclosed Round
Jun 2021
$46.5M
aMoon Fund (Lead)
,
Oriella Limited, Pavilion Capital, Hadasit Bio-Holdings, Shavit Capital Fund, Mirae Asset Venture Investment, Flerie Invest AB, Dafna Capital, BVF Partners, Cancer Focus Fund, Peregrine Ventures
C Round
Feb 2020
$18M
Flerie Invest AB (Lead)
,
Hadasit Bio-Holdings, Pavilion Capital, Oriella Limited, Mirae Asset Venture Investment
B Round
Dec 2015
$12M
Mirae Asset Venture Investment, Korea Investment Partners, DSC Investment, Flerie Invest AB
A Round
Sep 2013
$7.5M
Sanofi Ventures, Flerie Invest AB, Hadasit Bio-Holdings
Undisclosed Round
Dec 2011
$3M
Sanofi, Hadasit Bio-Holdings
Seed
Jan 2009
$500K
Hadasit Bio-Holdings, Office of the Chief Scientist
KAHR Medical Lifecycle
Cumulative Funding Raised Over Time
$3.0MDec 2011
$15.0MDec 2015
$33.0MFeb 2020
$33.5MJan 2009
$80.0MJun 2021
$97.5MJun 2023
$97.5MJun 2024
$97.5MMar 2024
$97.5MMay 2025
$110.0MNov 2022
$117.5MSep 2013
$117.5MSep 2025
All Events
Undisclosed Round
Sep 2025
Undisclosed
Peregrine Ventures
Undisclosed Round
May 2025
Undisclosed
Peregrine Ventures
Undisclosed Round
Jun 2024
Undisclosed
aMoon Fund
Undisclosed Round
Mar 2024
Undisclosed
Peregrine Ventures
F Round
Jun 2023
$17.5M
Peregrine Ventures
Undisclosed Round
Nov 2022
$12.5M
Myeloma Investment Fund
Undisclosed Round
Jun 2021
$46.5M
aMoon Fund (Lead)
,
Oriella Limited, Pavilion Capital, Hadasit Bio-Holdings, Shavit Capital Fund, Mirae Asset Venture Investment, Flerie Invest AB, Dafna Capital, BVF Partners, Cancer Focus Fund, Peregrine Ventures
C Round
Feb 2020
$18M
Flerie Invest AB (Lead)
,
Hadasit Bio-Holdings, Pavilion Capital, Oriella Limited, Mirae Asset Venture Investment
B Round
Dec 2015
$12M
Mirae Asset Venture Investment, Korea Investment Partners, DSC Investment, Flerie Invest AB
A Round
Sep 2013
$7.5M
Sanofi Ventures, Flerie Invest AB, Hadasit Bio-Holdings
Undisclosed Round
Dec 2011
$3M
Sanofi, Hadasit Bio-Holdings
Seed
Jan 2009
$500K
Hadasit Bio-Holdings, Office of the Chief Scientist
KAHR Medical News
15 articles
growth-positive
/PRNewswire/ -- KAHR, a clinical-stage biotech company developing DSP107, a first-in-class bi-specific 4-1BB T-cell engager that activates innate and adaptive...
KAHR, a clinical-stage biotech company, announced positive results from the Phase 2 dose expansion cohort of DSP107 in combination with atezolizumab for treating 3rd line microsatellite stable metastatic colorectal cancer (MSS-CRC). The combination therapy has shown anti-tumor activity and extended survival, including in patients with liver metastases. These results will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. DSP107 is a bi-specific 4-1BB T-cell engager that activates both innate and adaptive immunity, targeting CD47 overexpression on cancer cells. This approach is particularly relevant for MSS-CRC, a challenging subtype of colorectal cancer. KAHRs development of DSP107 aims to address the unmet medical need in treating MSS-CRC.
Product StageFDA approved/pending approval
growth-positive
KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors
KAHR, a clinical-stage biotech company, announced positive results from a Phase I study of its novel immunotherapy, DSP107, in combination with atezolizumab. The study, which focused on patients with advanced solid tumors, demonstrated significant tumor shrinkage and durable responses, particularly in patients with microsatellite stable colorectal cancer (MSS-CRC). The highest dose of DSP107 was selected for Phase II expansion cohorts, showing a disease control rate of 57%. The treatment was well tolerated with no dose-limiting toxicities. These promising results will be presented at the ASCO 2023 Annual Meeting. KAHRs DSP107 targets CD47 and 4-1BB, activating both innate and adaptive immunity to treat solid tumors and blood cancers.
growth-positive
MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma
KAHR Medical has received an investment from the Myeloma Investment Fund (MIF) to explore the potential of its leading immunotherapy drug candidate, DSP107, for the treatment of multiple myeloma. The investment reinforces KAHRs commitment to developing innovative treatment approaches for myeloma patients. With this investment, KAHR Medical has raised a total of $59 million since June 2021. DSP107 is a dual-targeting fusion protein that activates innate and adaptive immunity to bolster anti-tumor immunity. It has demonstrated a good safety profile and high disease control rates in a phase 1 trial. MIF is a venture philanthropy fund that invests in promising companies and technologies in oncology to drive the development of new therapies for multiple myeloma.
Investment
growth-positive
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
KAHR and Cancer Focus Fund have announced the dosing of the first patient in a Phase 1b clinical trial of DSP107, a CD47x41BB targeting fusion protein, in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The trial is being funded by an investment from Cancer Focus Fund. KAHRs CEO, Yaron Pereg, expressed gratitude for the support and highlighted the potential of DSP107 to achieve significant anti-tumor effects across cancer types. The trial is being conducted at MD Anderson and led by Naval Daver. DSP107 is also being tested in a Phase 1/2 clinical trial for solid tumor cancers. KAHR develops novel dual-targeting fusion protein therapeutics that activate both the innate and adaptive immune systems.
Investment
growth-positive
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Cancer immunotherapy company KAHR has announced the first closing of an investment round, raising $46.5 million. The financing, led by aMoon, will be used to advance the clinical development of the companys lead product candidate, DSP107, a CD47x41BB targeting fusion protein for the treatment of solid and blood cancers. The funding will also support the development of KAHRs preclinical pipeline. The successful financing round includes participation from new and existing investors. KAHRs unique approach to cancer immunotherapy aims to unmask cancer cells for immune recognition and trigger a targeted activation of anticancer immunity. The companys lead product candidate, DSP107, is currently being tested in Phase 1/2 studies. KAHRs technology platform utilizes multi-functional immuno-recruitment proteins to selectively target and bind to tumors.
Investment
growth-positive
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
Samsung Biologics has signed a strategic partnership with KAHR Medical to provide its development and manufacturing services for KAHRs drug candidate DSP502, a TIGITxPD1 fusion protein. The partnership aims to bring cutting-edge immuno-recruitment cancer drugs to patients in need. KAHR is an innovative leader in the fusion protein space, developing multi-functional immuno-recruitment proteins that selectively target tumors. Samsung Biologics, a leading contract development and manufacturing organization, offers integrated and high-quality development services. The partnership will leverage Samsung Biologics expertise to ensure the success of KAHRs drug candidate.
Partners
growth-positive
KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers
KAHR and Cancer Focus Fund announced that Cancer Focus Fund is investing $5 million to finance a clinical trial of KAHRs lead anti-CD47 candidate, DSP107, in blood cancers. The investment will support a Phase 1/2 clinical study assessing KAHRs CD47x41BB targeting agent in the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and T-cell lymphoproliferative diseases. The study will be conducted at MD Anderson. DSP107 is a first-in-class CD47x41BB targeting compound that simultaneously targets cancer cells and activates an effective immune response. KAHR is a clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins.
Investment
growth-positive
KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy
KAHR has entered into a licensing agreement with Thomas Jefferson University to develop and commercialize multiple new drug candidates for immuno-oncology. The agreement adds a second fusion protein platform to KAHRs portfolio, positioning the company as a world leader in the fusion protein space. The licensed drug candidates focus on promising checkpoint pathways and target ligands instead of receptors, increasing tumor selectivity. The collaboration with Thomas Jefferson University allows for the expansion of the platform into novel targets and the activation of other immune cell types. KAHRs current technology is based on multi-functional immuno-recruitment proteins that selectively target cancer cells. The companys lead asset, DSP107, is currently being evaluated in a Phase 1/2 study. KAHRs investors include Flerie Invest AB, Oriella Limited, Hadassit Bio Holdings, Pavilion Capital, Mirae Asset, Korean Investment Partners, and DSC Investments.
Partners
growth-positive
https://www.jpost.com/health-science/jerusalem-based-firm-starts-clinical-trials-for-cancer-treatment-648952
Cancer immunotherapy company KAHR has announced the dosing of its first patient in the Phase 1/2 clinical trial for its treatment of solid tumors. The drug, known as DSP107, works by simultaneously targeting cancer cells, weakening their defense mechanisms, and activating the bodys innate and adaptive immune systems to work against the cells. The study will be conducted at multiple leading sites in the United States in collaboration with Roche.
CustomersPartners
growth-positive
KAHR Announces Addition of Prof. Hagop M. Kantarjian to Its Clinical Advisory Board
Prof. Hagop M. Kantarjian, a world leader in leukemia treatment, has joined KAHRs clinical advisory board. KAHR is a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins. Prof. Kantarjians expertise will contribute to the advancement of KAHRs CD47x41BB targeting compound for the treatment of hematological malignancies. KAHRs clinical advisory board also includes other renowned experts in the field. The companys technology platform is based on multi-functional immuno-recruitment proteins that selectively target and bind to tumors, activating both innate and adaptive immunity. KAHR has received investments from Flerie Invest AB, Oriella Limited, Hadassit Bio-Holdings, Pavilion Capital, Mirae Asset, Korean Investment Partners, and DSC Investments.
Partners
growth-positive
KAHR Medical gets FDA nod to start human trials for cancer drug
Israeli biopharmaceutical company KAHR Medical has received FDA clearance to start clinical trials on its immunotherapy drug, DSP-107, to battle cancer. The drug targets cancer cells, weakens their defenses, and activates a local response. KAHR plans to conduct a Phase I/II clinical trial to evaluate the drugs safety and effectiveness. The trial will test DSP-107 as a stand-alone treatment and in combination with another immunotherapy medication developed by Roche. KAHR has raised $18 million to date from various investors.
Investment
growth-positive
Cancer Treatment Company KAHR Medical Raises $18 Million
Jerusalem-based biopharma company KAHR Medical Ltd. has raised $18 million in funding. The company plans to use the funding to advance its immuno-oncology drug candidates, particularly its lead product, DSP107, which targets CD47 and is being tested for the treatment of solid tumors.
Investment
growth-positive
KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients BioSpace
KAHR Medical has announced a new clinical collaboration with Roche to explore the potential of combining KAHRs lead program, DSP107, with Roches checkpoint inhibitor atezolizumab in treating advanced NSCLC patients. The collaboration aims to evaluate the safety, efficacy, and pharmacokinetics of DSP107 as a monotherapy and in combination with atezolizumab. DSP107 is a bi-functional, immunotherapeutic fusion protein that targets CD47-overexpressing tumors and stimulates immune activation. The Phase I/II trial is expected to begin in H1 2020. KAHR Medical is optimistic about the potential of this collaboration to provide treatment options for NSCLC patients with limited options.
Partners
growth-positive
Canada-Israel sign business deals worth $87 million
Ontario Premier Kathleen Wynne signed 18 agreements and partnerships valued at $87 million during a trade mission to Israel. The focus of the visit was on the life sciences and research sectors. Ontario business leaders are seeking Israeli innovation ideas and offering tax breaks in return. Two-way trade between Ontario and Israel last year was valued at over $900 million. The agreements include collaborations in various fields such as healthcare, technology, and education.
Partners
growth-positive
Israeli cancer treatment co KAHR Medical raises $12m
KAHR Medical Ltd has raised $12 million in a Series B financing round, with a total financing round of $15 million. The funding will be used to fund the clinical development of KAHRs lead product, KAHR-102, and the pre-clinical development of KAHR-101 and new pipeline programs. The investors in the financing round include Korea Investment Partners, Mirae Asset Venture Investment, DSC Investment, and Flerie Invest AB. The CEO of KAHR Medical, Dr. Noam Shani, stated that the funding will allow the company to advance their lead products through pre-clinical and clinical development stages.
Investment
KAHR Medical Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 25 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
KAHR Medical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 513736249 |
| Crunchbase | kahr-medical |
| Phone | +972737969196 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-11-12T00:00:00.000Z |
| Created | 2014-07-29T00:00:00.000Z |